Nigeria has achieved a significant milestone in HIV prevention with the arrival of Lenacapavir, a long-acting injection administered just twice a year, offering a new strategy to reduce new infections. The shipment, confirmed on Thursday, March 12, 2026, by the National AIDS, Viral Hepatitis and STIs Control Programme under the Federal Ministry of Health and Social Welfare, reached the country on March 10.
Lenacapavir will be deployed as pre-exposure prophylaxis (PrEP), providing preventive treatment for HIV-negative individuals at risk of infection. The biannual dosing model addresses challenges associated with daily oral HIV medications, improving adherence and offering greater convenience for populations who struggle with daily pill regimens.
Read Also:
- Nigeria secures breakthrough HIV prevention injection at just $40, down from $28,000, at UN Assembly
- Landmark deal paves the way for cheaper HIV protection jab
- NACA announces seventh national council on AIDS in Lagos to tackle Nigeria’s HIV response
The rollout, endorsed by Coordinating Minister of Health and Social Welfare Muhammad Ali Pate and supported by the Global Fund, signals a landmark moment in Nigeria’s public health strategy. Officials confirm that preparations are underway to integrate Lenacapavir into the national HIV prevention program, enhancing access to lifesaving prevention tools and advancing the country’s goal of controlling the epidemic.
Experts say the introduction of Lenacapavir represents a major step toward strengthening Nigeria’s HIV response, expanding prevention options, and improving health outcomes for at-risk populations across the nation.
